apollo
0

Welcome User

Login/Sign Up

Home
Buy Medicines
Lab Tests
Doctor Consult
Circle Membership
Insurance
Blogs
Contact Us
Privacy Policy
Return & Refunds
Need Help
Terms and Conditions
  1. Home
  2. Medicine

  3. Lorbriqua 25 mg Tablet 30's

Lorbriqua 25 mg Tablet 30's, Pack of 1 TABLET
Written By Bayyarapu Mahesh Kumar , M Pharmacy
Reviewed By Sureshvarma D , MPharma
Non returnable*
Know More
COD available

Online payment accepted

rxMedicinePrescription drug

Whats That

tooltip

Composition :

LORLATINIB-25MG

Manufacturer/Marketer :

Pfizer Ltd

Consume Type :

ORAL

Return Policy :

Not Returnable

Expires on or after :

About Lorbriqua 25 mg Tablet

Lorbriqua 25 mg Tablet belongs to the group of medicines that inhibit an enzyme called anaplastic lymphoma kinase (ALK). It is used to treat adults with advanced stages of lung cancer called non-small cell lung cancer (NSCLC). Non-small cell lung cancer is a disease in which malignant (cancer) cells form in the lung tissues. There are several types of non-small cell lung cancer. Smoking is the major risk factor for non-small cell lung cancer.

Lorbriqua 25 mg Tablet contains the active substance Lorlatinib, a medicine used to treat adults with advanced stages of a form of lung cancer called non-small cell lung cancer (NSCLC). It works by inhibiting a type of enzyme called tyrosine kinase and triggers the death of cancer cells in patients with alterations in genes for ALK. Lorbriqua 25 mg Tablet is only given to patients whose disease is due to an alteration in the gene for ALK tyrosine kinase.

Always use this medicine as your doctor has told you or per the package leaflet. You must keep to your doctor's instructions to get the maximum benefit. In some cases, you may experience common side effects such as diarrhoea, constipation, joint pain, weight gain, headache, rash, and muscle pain. Most of these side effects do not require medical attention and will resolve gradually over time. However, you are advised to talk to your doctor if you experience these side effects persistently.

Consult your doctor before taking Lorbriqua 25 mg Tablet if you are pregnant or breastfeeding. Lorbriqua 25 mg Tablet may cause tiredness and dizziness, so drive with caution. Avoid consuming alcohol with Lorbriqua 25 mg Tablet as it could lead to increased dizziness. Lorbriqua 25 mg Tablet is not recommended for children below 18 years as safety and effectiveness have not been established. Lorbriqua 25 mg Tablet is listed as pregnancy category D. Because Lorbriqua 25 mg Tablet can cause harm to the fetus, women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with Lorbriqua 25 mg Tablet . Consult your doctor if you are breastfeeding; your doctor will decide whether Lorbriqua 25 mg Tablet can be taken by breastfeeding mothers or not. Keep your doctor informed about your health condition and medicines to rule out any side effects. Lorbriqua 25 mg Tablet may affect male fertility. Talk to your doctor about fertility preservation before taking Lorbriqua 25 mg Tablet .

Uses of Lorbriqua 25 mg Tablet

Treatment of advanced stages of lung cancer called non-small cell lung cancer (NSCLC)

Directions for Use

Swallow it as a whole with water; do not crush, break or chew it.

Medicinal Benefits

Lorbriqua 25 mg Tablet contains the active substance Lorlatinib, a medicine used to treat adults with advanced stages of a form of lung cancer called non-small cell lung cancer (NSCLC). Lorbriqua 25 mg Tablet is only given to patients whose disease is due to an alteration in the gene for ALK tyrosine kinase. It works by inhibiting a type of enzyme called tyrosine kinase and triggers the death of cancer cells in patients with alterations in genes for ALK.

Storage

Store in a cool and dry place away from sunlight

Drug Warnings

Consult your doctor before taking Lorbriqua 25 mg Tablet if you are pregnant or breastfeeding. Lorbriqua 25 mg Tablet may cause tiredness and dizziness, so drive with caution. Avoid consuming alcohol with Lorbriqua 25 mg Tablet as it could lead to increased dizziness. Lorbriqua 25 mg Tablet is not recommended for children below 18 years as safety and effectiveness have not been established. Lorbriqua 25 mg Tablet is listed as pregnancy category D. Because Lorbriqua 25 mg Tablet can cause harm to the fetus, women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with Lorbriqua 25 mg Tablet . Consult your doctor if you are breastfeeding; your doctor will decide whether the Lorbriqua 25 mg Tablet can be taken by breastfeeding mothers or not. Keep your doctor informed about your health condition and medicines to rule out any side effects. Lorbriqua 25 mg Tablet may affect male fertility. Talk to your doctor about fertility preservation before taking Lorbriqua 25 mg Tablet .

Diet & Lifestyle Advise

  • Watch out for triggers that worsen the cough, such as smoke, foods, air-conditioning, high altitude, etc.
  • Exercise moderately. Eat healthily.
  • Follow pulmonary rehabilitation program. It includes exercise, disease education, and group therapy.
  • Quit smoking and alcohol.
  • Get ample rest.
  • Include green leafy vegetables, sweet potatoes, broccoli, tomatoes, carrots, mangoes, citrus fruits, berries, and cocoa.
  • Lean proteins such as fish, meat, and poultry are the best.
  • Hydration is important. Drink plenty of water, herbal tea, and vegetable and fruit juices.
  • Avoid processed and refined foods.

Habit Forming

No

Therapeutic Class

ANTINEOPLASTIC

Lorbriqua 25 mg Tablet Substitute

Substitutes safety advice

Product Substitutes

Author Details

Bayyarapu Mahesh KumarDoctor badge

Written By

Bayyarapu Mahesh Kumar

M Pharmacy

Sureshvarma D

Reviewed By

Sureshvarma D

MPharma

Last Updated

Jul 8, 2025 | 9:40 AM IST

Doctor imageWe provide you with authentic, trustworthy and relevant information

FAQs

Lorbriqua 25 mg Tablet contains the active substance Lorlatinib, which inhibits a type of enzyme called tyrosine kinase and triggers the death of cancer cells in patients with alterations in genes for ALK. Lorbriqua 25 mg Tablet is only given to patients whose disease is due to an alteration in the gene for ALK tyrosine kinase.

Lorlatinib belongs to the kinase inhibitor class of drugs. Lorlatinib is a drug used to treat a kind of non-small cell lung cancer (NSCLC) that has spread to other places of the body in adults. It works by preventing the malfunctioning protein from causing cancer cells to multiply.

Lorbriqua 25 mg Tablet should be stopped when a person faces a serious side effect that affects life quality. Otherwise, it would be best to keep taking Lorbriqua 25 mg Tablet until your doctor asks you to stop it.

Avoid smoking before starting the treatment while taking Lorbriqua 25 mg Tablet as smoking might alter the effectiveness of Lorbriqua 25 mg Tablet .

In elderly patients, the risk of side effects is greater. For the elderly, dose adjustment might be required, or your doctor might prescribe any other medication safe for the elderly.

You should complete the full course of Lorbriqua 25 mg Tablet as your doctor prescribes. After completing the full course of Lorbriqua 25 mg Tablet will work. It would help if you took Lorbriqua 25 mg Tablet at the right dose, right times and for the right number of days.

Detecting lung cancer in its early stages, when it is most treatable, is critical to survival. Early tumours have a cure rate of 85-90 per cent, but this depends on other factors.

Drug-Drug Interactions Checker List

  • KETOCONAZOLE
  • ITRACONAZOLE
  • ERYTHROMYCIN
  • QUINIDINE
  • ALFENTANIL
  • FENTANYL
  • CICLOSPORIN
  • SIROLIMUS
  • TACROLIMUS
  • EFAVIRENZ
  • COBICISTAT
  • BUPRENORPHINE
  • DIHYDROERGOTAMINE
  • ERGOTAMINE
  • BUPROPION
  • BOCEPREVIR

Special Advise

You will have blood tests before you start treatment and during your treatment. These tests check the level of cholesterol, triglycerides and the enzymes amylase or lipase in your blood before you start treatment with Lorbriqua 25 mg Tablet and regularly during treatment. You will have blood tests before you start treatment and during your treatment. These tests check the level of cholesterol, triglycerides and the enzymes amylase or lipase in your blood before you start treatment with Lorbriqua 25 mg Tablet and regularly during treatment.

Disease/Condition Glossary

Non-small cell lung cancer (NSCLC): Non-small cell lung cancer (NSCLC) is a disease in which malignant (cancer) cells form in the lung tissues. There are several types of non-small cell lung cancer. Smoking is the major risk factor for non-small cell lung cancer.

Have a query?

Buy best Neoplastic Disorders products by

whatsapp Floating Button